Some realityIts great getting FDA Priority review but Its just a step. Much harder to get FDA approval and there are multiple points of resistance on the long term chart. First at about .56 to .61 and more all the way up to $1.80ish. The stock will have to grind higher through all those points of resistance. Also, we now have about 200 million shares or somewhere in that area. It will take a lot of trading to go higher.